Effects of sarcoma 180 growth on interleukin-1 and circulating immune complexes

Cultured splenic mononuclear adherent cells (SMAc) from normal BALB/c mice as well as those from mice bearing 10-day sarcoma 180 (S180), exhibited a marked increase in Escherichia coli lipopolysaccharide-stimulated interleukin-1 (IL-1) production, when compared to spontaneous values. On days 20 and...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Chasseing, N.A
Otros Autores: Eugui, E.M, Borda, E.S, Rumi, L.
Formato: Capítulo de libro
Lenguaje:Inglés
Publicado: Informa Healthcare 1994
Acceso en línea:Registro en Scopus
DOI
Handle
Registro en la Biblioteca Digital
Aporte de:Registro referencial: Solicitar el recurso aquí
LEADER 06710caa a22009737a 4500
001 PAPER-19142
003 AR-BaUEN
005 20230518205030.0
008 190411s1994 xx ||||fo|||| 00| 0 eng|d
024 7 |2 scopus  |a 2-s2.0-0027964258 
024 7 |2 cas  |a prostaglandin E2, 363-24-6; Antigen-Antibody Complex; Dinoprostone, 363-24-6; Interleukin-1; Lipopolysaccharides 
040 |a Scopus  |b spa  |c AR-BaUEN  |d AR-BaUEN 
030 |a CINVD 
100 1 |a Chasseing, N.A. 
245 1 0 |a Effects of sarcoma 180 growth on interleukin-1 and circulating immune complexes 
260 |b Informa Healthcare  |c 1994 
270 1 0 |m Chasseing, N.A.; Instituto de Biología y Medicina Experimental, Obligado 2490, CP 1428, Buenos Aires, Argentina 
506 |2 openaire  |e Política editorial 
504 |a Currie, G.A., Activated macrophages kill tumor cells by releasing arginase (1978) Nature, 273, pp. 758-759 
504 |a Matthews, N., Neale, M.L., Jackson, S.K., Tumor cell killing by tumor necrosis factor: Inhibition by anaerobic conditions, freeradical scavengers and inhibitors or arachidonate metabolism (1987) Immunology, 62, pp. 153-155 
504 |a Meltzer, M.S., Macrophage activation for tumor cytotoxicity: Characterization of priming and trigger signals during lymphokine activation (1981) J Immunol, 127, pp. 179-183 
504 |a Fryling, C., Dombalagain, M., Burgess, W., Purification and characterization of tumor inhibitory factor-2: Its identity to inlerleukin 1 (1989) Cancer Res, 49, pp. 3333-3337 
504 |a Onazaki, K., Matushima, K., Kleirerman, E.S., Role of interleukin-1 in promoting human monocyte-mediated tumor cytotoxicity (1985) J Immunol, 135, pp. 314-320 
504 |a Chasseing, N.A., Doria Medina, P., Lederkremer, R.M., Produccion de Interleuquina-I durante el crecimiento tumoral (1989) Medicina (Buenos Aires), 49, pp. 271-276 
504 |a Fruehauf, J.P., Bonnard, G.D., Heberman, R.B., The effect of lentinan on production of interleukin-I human monocytes (1982) Immunopharmacology, 5, pp. 65-74 
504 |a Creighton, W., Lambert, P.H., Meischer, P.A., Detection of antibodies and soluble antigen-antibody complexes by precipitation with polyethyleneglycol (1973) J Immunol, 111, pp. 1219-1227 
504 |a Herman, J., Kew, M.C., Rabson, A.R., Defective interleukin-1 production by monocytes from patients with malignant disease. Interferon increases interleukin-1 production (1984) Cancer Immunol Immunother, 16, pp. 182-185 
504 |a Ravikumar, T., Stell, G., Rodrick, M., Effects of tumor-growth on interleukins and circulating immune complexes (1984) Cancer, 53, pp. 1373-1378 
504 |a Knudsen, P.J., Dinarello, C.A., Strom, T.B., Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin-1 activity by increasing intracellular cyclic adenosine monophosphate (1986) J Immunol, 137, pp. 3189-3194 
520 3 |a Cultured splenic mononuclear adherent cells (SMAc) from normal BALB/c mice as well as those from mice bearing 10-day sarcoma 180 (S180), exhibited a marked increase in Escherichia coli lipopolysaccharide-stimulated interleukin-1 (IL-1) production, when compared to spontaneous values. On days 20 and 30 following S180 challenge, a decrease in this effect on IL-1 production in treated and untreated SMAc was observed. Concomitantly with the alterations in the regulation of IL-1 production during tumor growth, an increase in the levels of prostaglandin E2 and serum immune complexes could be detected. These data suggest that the immunosuppression associated with later stages of tumor development may be due to direct effects on monocytes, by means of a down-regulation of IL-1 production. © 1994 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.  |l eng 
536 |a Detalles de la financiación: National Council for Scientific Research 
536 |a Detalles de la financiación: We thank Dr. Horacio Bordenave and Leonor Stein Borda for their useful comments on the manuscript and Patricia Doria Medina and Maria Elena Sales for their technical assistance with the PGE, radioimmunoassays. This study was supported by the National Research Council of Argentina (Consejo Nacional de lnvestigaciones Cientificas y Tecnicas de la Argentina. CONICET). 
593 |a Instituto de Biologia y Medicina Experimental Obligado, 2490 1428, Buenos Aires, Argentina 
593 |a Institute of Biological Sciences Syntex Research, 3401 Hillview Avenue, Palo Alto, CA, 94304, United States 
593 |a Centro de Estudios Farmacológicos y Botánicos (CEFYBO) Serrano, 665, Buenos Aires, Argentina 
690 1 0 |a ESCHERICHIA COLI LIPOPOLYSACCHARIDE 
690 1 0 |a INTERLEUKIN 1 
690 1 0 |a PROSTAGLANDIN E2 
690 1 0 |a ANIMAL CELL 
690 1 0 |a ANIMAL EXPERIMENT 
690 1 0 |a ANIMAL MODEL 
690 1 0 |a ANTIGEN ANTIBODY COMPLEX 
690 1 0 |a ARTICLE 
690 1 0 |a CANCER GROWTH 
690 1 0 |a CARCINOGENESIS 
690 1 0 |a CONTROLLED STUDY 
690 1 0 |a FEMALE 
690 1 0 |a HOST RESISTANCE 
690 1 0 |a IMMUNOMODULATION 
690 1 0 |a MONONUCLEAR CELL 
690 1 0 |a MOUSE 
690 1 0 |a NONHUMAN 
690 1 0 |a PRIORITY JOURNAL 
690 1 0 |a SARCOMA CELL 
690 1 0 |a TUMOR IMMUNITY 
690 1 0 |a ANIMAL 
690 1 0 |a ANTIGEN-ANTIBODY COMPLEX 
690 1 0 |a CELL ADHESION 
690 1 0 |a CELL DIVISION 
690 1 0 |a DINOPROSTONE 
690 1 0 |a ESCHERICHIA COLI 
690 1 0 |a EVALUATION STUDIES 
690 1 0 |a FEMALE 
690 1 0 |a INTERLEUKIN-1 
690 1 0 |a LIPOPOLYSACCHARIDES 
690 1 0 |a MICE 
690 1 0 |a MICE, INBRED BALB C 
690 1 0 |a MICE, INBRED C3H 
690 1 0 |a MONOCYTES 
690 1 0 |a NEOPLASM TRANSPLANTATION 
690 1 0 |a SARCOMA 180 
690 1 0 |a SPLEEN 
690 1 0 |a SUPPORT, NON-U.S. GOV'T 
700 1 |a Eugui, E.M. 
700 1 |a Borda, E.S. 
700 1 |a Rumi, L. 
773 0 |d Informa Healthcare, 1994  |g v. 12  |h pp. 390-394  |k n. 4  |p Cancer Invest.  |x 07357907  |w (AR-BaUEN)CENRE-4107  |t Cancer Investigation 
856 4 1 |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-0027964258&doi=10.3109%2f07357909409038228&partnerID=40&md5=4d234f68c77d34f8acc821e262c50e5b  |y Registro en Scopus 
856 4 0 |u https://doi.org/10.3109/07357909409038228  |y DOI 
856 4 0 |u https://hdl.handle.net/20.500.12110/paper_07357907_v12_n4_p390_Chasseing  |y Handle 
856 4 0 |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_07357907_v12_n4_p390_Chasseing  |y Registro en la Biblioteca Digital 
961 |a paper_07357907_v12_n4_p390_Chasseing  |b paper  |c PE 
962 |a info:eu-repo/semantics/article  |a info:ar-repo/semantics/artículo  |b info:eu-repo/semantics/publishedVersion 
999 |c 80095